Clinical Drug Investigation

, Volume 22, Supplement 2, pp 43–52 | Cite as

Desloratadine in the Treatment of Seasonal Allergic Rhinitis

Results of a Large Observational Study
  • Claus Bachert
  • Christian J. VirchowJr
  • Astrid Plenker
Original Research Article

Abstract

Objective: To assess the efficacy and safety of desloratadine in the treatment of seasonal allergic rhinitis (SAR) in the clinical setting.

Design and Setting: The postmarketing surveillance study was performed in Germany in 47 953 outpatients requiring treatment of SAR between February and October 2001.

Results: The mean duration of desloratadine treatment was 38.4 days and compliance was rated as good/excellent in 98% of cases. Mean nasal, ocular, asthma, dermal and total symptom sum scores were reduced significantly during desloratadine treatment compared with baseline (p = 0.0001). Interference with daily activity and sleep disturbance decreased markedly during desloratadine therapy. Of patients with SAR and asthma symptoms at baseline, 50.7% also reduced their asthma medication during desloratadine treatment. The global efficacy of desloratadine was rated as good/excellent by 91.2% of patients and 92.6% of physicians. Global safety/tolerability was rated as good/excellent by 98.9% of physicians and 98.5% of patients and the adverse event rate was very low (0.44%). Onset of symptom relief following desloratadine was rated as faster than previous treatment by 64.1% of physicians and 65.7% of patients.

Conclusions: This study supports the evidence from placebo-controlled trials that desloratadine is an effective and well tolerated treatment for SAR symptoms, including nasal congestion. Desloratadine provided significant relief of other associated problems, including related asthma and dermal symptoms.

References

  1. 1.
    Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991; 21: 77–83PubMedCrossRefGoogle Scholar
  2. 2.
    Juniper EF, Howland WC, Roberts NB, et al. Measuring quality of life in children with rhinoconjunctivitis. J Allergy Clin Immunol 1998; 101: 163–70PubMedCrossRefGoogle Scholar
  3. 3.
    Simons FE. Learning impairment and allergic rhinitis. Allergy Asthma Proc 1996; 17: 185–9PubMedCrossRefGoogle Scholar
  4. 4.
    Daly AF. Desloratadine reduces nasal congestion in SAR with greater magnitude than fexofenadine, cetirizine and loratadine. Allergy 2001; 56 Suppl. 68: 230Google Scholar
  5. 5.
    Young T, Finn L, Kim H. Nasal obstruction as a risk factor for sleep-disordered breathing. The University of Wisconsin Sleep and Respiratory Research Group. J Allergy Clin Immunol 1997 Feb; 99(2): S757–62PubMedCrossRefGoogle Scholar
  6. 6.
    Finn L, Young T, Palta M, et al. Sleep-disordered breathing and self-reported general health status in the Wisconsin Sleep Cohort Study. Sleep 1998 Nov 1; 21(7): 701–6PubMedGoogle Scholar
  7. 7.
    Spector SL. Overview of comorbid associations of allergic rhinitis. J Allergy Clin Immunol 1997 Feb; 99(2): S773–80PubMedCrossRefGoogle Scholar
  8. 8.
    Vignola AM, Chanez P, Godard P, et al. Relationships between rhinitis and asthma. Allergy 1998 Sep; 53(9): 833–9PubMedCrossRefGoogle Scholar
  9. 9.
    Broide DH. Molecular and cellular mechanisms of allergic disease. J Allergy Clin Immunol 2001 Aug; 108 Suppl. 2: S65–71PubMedCrossRefGoogle Scholar
  10. 10.
    Kay AB. Allergy and allergic diseases (part 1 of 2). N Engl J Med 2001; 344(1): 30–7PubMedCrossRefGoogle Scholar
  11. 11.
    Kreutner W, Hey JA, Anthes J, et al. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergic effects. Arzneimittelforschung 2000; 50: 345–52PubMedGoogle Scholar
  12. 12.
    Meltzer EO, Prenner BM, Nayak A, et al. Efficacy and tolerability of once-daily desloratadine, an H1-receptor antagonist, in patients with seasonal allergic rhinitis. Clin Drug Invest 2001; 21(1): 25–32CrossRefGoogle Scholar
  13. 13.
    Ring J, Hein R, Gauger A, et al. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol 2001;40: 1–5CrossRefGoogle Scholar
  14. 14.
    Geha RS, Meltzer EO. Desloratadine: a new, nonsedating, oral antihistamine. J Allergy Clin Immunol 2001; 107(4): 751–6PubMedCrossRefGoogle Scholar
  15. 15.
    Bachert C. Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis. Allergy 2001; 56 Suppl. 65: 14–20PubMedCrossRefGoogle Scholar
  16. 16.
    Nayak AS, Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 2001 Nov;56(11): 1077–80PubMedCrossRefGoogle Scholar
  17. 17.
    Horak F, Stubner P, Zieglmayer R, et al. Desloratadine reduces nasal congestion and maintains nasal airflow in patients with seasonal allergic rhinitis exposed to allergen in the Vienna Challenge Chamber [abstract]. Allergy 2001; 56 Suppl. 68: 1000Google Scholar
  18. 18.
    Henz BM. The pharmacologic profile of desloratadine: a review. Allergy 2001; 56 Suppl. 65: 7–13PubMedCrossRefGoogle Scholar
  19. 19.
    Charatan F. Bayer decides to withdraw cholesterol lowering drug. BMJ 2001; 323(7309): 359CrossRefGoogle Scholar
  20. 20.
    Henney JE. Withdrawal of troglitazone and cisapride. JAMA 2000; 283(17): 2228CrossRefGoogle Scholar
  21. 21.
    Talk Paper. Roche Laboratories announces withdrawal of Posicor from the market (1998 Jun 8). Available from URL: http://www.fda.gov/bbs/topics/ANSWERS/ANS00876.html. [Accessed 2002 Apr 19]
  22. 22.
    Kupec IF. Seldane and generic terfenadine withdrawn from market (1998 Feb 27). Available from URL: http://www.fda.gov/bbs/topics/ANSWERS/ANS00853.html. [Accessed 2002 Apr 19]
  23. 23.
    Friedman MA, Woodcock J, Lumpkin MM, et al. The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA 1999; 281(18): 1728–34PubMedCrossRefGoogle Scholar
  24. 24.
    Koh KK, Rim MS, Yoon J, et al. Torsade de pointes induced by terfenadine in a patient with long QT syndrome. J Electrocardiol 1994; 27(4): 343–6PubMedCrossRefGoogle Scholar
  25. 25.
    Baena-Cagnani C, the Desloratadine Study Group. Desloratadine improved asthma symptoms and decreased β2 agonist use in patients with seasonal allergic rhinitis and asthma. Allergy 2001; 56 Suppl. 68: 60Google Scholar
  26. 26.
    Grant JA, Nicodemus CF, Findlay SR, et al. Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol 1995; 95(5 Pt 1): 923–32PubMedCrossRefGoogle Scholar
  27. 27.
    Corren J, Harris AG, Aaronson D, et al. Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. J Allergy Clin Immunol 1997; 100(6 Pt 1): 781–8PubMedCrossRefGoogle Scholar
  28. 28.
    Bousquet J, Van Cauwenberge P, Khaltaev N. Aria Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108 Suppl. 5: S147–334PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  • Claus Bachert
    • 1
  • Christian J. VirchowJr
    • 2
  • Astrid Plenker
    • 3
  1. 1.Dep. NKO, Department of ENTUniversity of GhentGhentBelgium
  2. 2.Department of PneumologyUniversity Medical ClinicRostockGermany
  3. 3.Essex PharmaMunichGermany

Personalised recommendations